Area of research
Surgery · Oncology
Research interest
Research interests include Colorectal and Anal Carcinomas, Colorectal Cancer Surgical Treatments, Gastric Cancer Management and Outcomes, and Esophageal Cancer Research and Treatment.
Clinicogenomic and Histopathologic Analyses of Supermassive Intrahepatic Cholangiocarcinoma and the Role of Ablative Radiotherapy.
Supplemental Table S4 from Secondary Endpoint Utilization and Publication Rate among Phase III Oncology Trials
Supplemental Table S7 from Secondary Endpoint Utilization and Publication Rate among Phase III Oncology Trials
Supplemental Table S6 from Secondary Endpoint Utilization and Publication Rate among Phase III Oncology Trials
Supplemental Table S1 from Secondary Endpoint Utilization and Publication Rate among Phase III Oncology Trials
Supplemental Table S5 from Secondary Endpoint Utilization and Publication Rate among Phase III Oncology Trials
Supplemental Table S3 from Secondary Endpoint Utilization and Publication Rate among Phase III Oncology Trials
Supplemental Table S2 from Secondary Endpoint Utilization and Publication Rate among Phase III Oncology Trials
Supplemental Figure S1 from Secondary Endpoint Utilization and Publication Rate among Phase III Oncology Trials
Secondary Endpoint Utilization and Publication Rate among Phase III Oncology Trials.
Lost in the plot: missing visual elements in Kaplan-Meier plots of phase III oncology trials.
Supplemental Table S2 from Secondary Endpoint Utilization and Publication Rate among Phase III Oncology Trials
Supplemental Figure S1 from Secondary Endpoint Utilization and Publication Rate among Phase III Oncology Trials
Table 3 from Secondary Endpoint Utilization and Publication Rate among Phase III Oncology Trials
Supplemental Table S2 from Secondary Endpoint Utilization and Publication Rate among Phase III Oncology Trials
Supplemental Table S2 from Secondary Endpoint Utilization and Publication Rate among Phase III Oncology Trials
Supplemental Figure S1 from Secondary Endpoint Utilization and Publication Rate among Phase III Oncology Trials
Supplemental Figure S1 from Secondary Endpoint Utilization and Publication Rate among Phase III Oncology Trials
Supplemental Table S4 from Secondary Endpoint Utilization and Publication Rate among Phase III Oncology Trials
Supplemental Table S3 from Secondary Endpoint Utilization and Publication Rate among Phase III Oncology Trials
Supplemental Table S1 from Secondary Endpoint Utilization and Publication Rate among Phase III Oncology Trials
Table 1 from Secondary Endpoint Utilization and Publication Rate among Phase III Oncology Trials
Supplemental Table S6 from Secondary Endpoint Utilization and Publication Rate among Phase III Oncology Trials
Supplemental Table S7 from Secondary Endpoint Utilization and Publication Rate among Phase III Oncology Trials
Supplemental Table S4 from Secondary Endpoint Utilization and Publication Rate among Phase III Oncology Trials
Supplemental Table S5 from Secondary Endpoint Utilization and Publication Rate among Phase III Oncology Trials
Table 3 from Secondary Endpoint Utilization and Publication Rate among Phase III Oncology Trials
Supplemental Table S7 from Secondary Endpoint Utilization and Publication Rate among Phase III Oncology Trials
Supplemental Table S3 from Secondary Endpoint Utilization and Publication Rate among Phase III Oncology Trials
Supplemental Table S7 from Secondary Endpoint Utilization and Publication Rate among Phase III Oncology Trials